The sensitivity of transmitted/founder HIV-1 to anti-HIV drugs
10.16438/j.0513-4870.2015-0359
- VernacularTitle:HIV-1初始传播病毒药物敏感性研究
- Author:
Ji-wei DING
1
;
Jian-yuan ZHAO
1
;
Ze-yun MI
1
;
Tao WEI
2
;
Shan CEN
1
Author Information
1. Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
2. College of Arts and Science of Beijing Union University, Beijing 100192, China
- Publication Type:ORIGINAL ARTICLES
- Keywords:
HIV-1;
pre-exposure prophylaxis;
founder virus;
reporter gene;
anti-HIV drug
- From:
Acta Pharmaceutica Sinica
2016;51(3):367-
- CountryChina
- Language:Chinese
-
Abstract:
The majority of mucosal HIV-1 infection is initially established by a few HIV-1 viral variants, followed by the development of overt systemic infection, and these viral variants are known as transmitted/founder viruses (T/F viruses). Investigation of the sensitivity of T/F virus to different anti-HIV-1 drugs will provide the best strategies of pre-exposure prophylaxis (PrEP) for high-risk groups of HIV-infected patients. Herein we constructed for the first time, a luciferase reporter system for HIV-1 T/F viruses, and then compared the drug sensitivity between T/F viruses and chronic infection virus. The result showed that the 50% inhibitory concentration (IC50) of nucleoside reverse transcriptase inhibitors (NRTIs), integrase inhibitors (INIs) and protease inhibitors (PIs) were not significantly different between the T/F viruses and chronic infection viruses of the same subtype (P>0.05), while non-nucleoside reverse transcriptase inhibitors (NNRTIs) showed a moderate resistance to T/F viruses, with a significant increase in IC50 (P<0.05). The conclusion suggests that when patients are in high-risk or in the acute infection of HIV-1, NNRTIs should be avoided in the first-line antiretroviral therapy regimens.
